Table 4.
Compliance among the three groups during 12 weeks of treatment.
MET group (n = 54) | SPI group (n = 53) | COM group (n = 51) | |
---|---|---|---|
Nausea | 6 (11.1%) | 3 (5.88%) | 5 (9.43%) |
Diarrhea | 3 (1.67%) | 2 (3.92%) | 3 (5.66%) |
Vomiting | 1 (1.85%) | 0 | 1 (1.89%) |
Polyuria | 0 | 1 (1.96%) | 0 |
Dry mouth | 0 | 2 (3.92%) | 0 |
MET: metformin; SPI: spironolactone; COM: combined.